Financial Performance - Total revenue for Q2 2023 was $0, compared to $10 million in Q2 2022, indicating a 100% decrease year-over-year[16] - Operating expenses for Q2 2023 were $8.99 million, a slight decrease of 6.5% from $9.62 million in Q2 2022[16] - Net loss for Q2 2023 was $8.76 million, compared to a net income of $414,000 in Q2 2022, reflecting a significant decline in financial performance[16] - The company reported a comprehensive loss of $8.79 million for Q2 2023, compared to a comprehensive income of $278,000 in Q2 2022[16] - Basic loss per share for Q2 2023 was $0.10, compared to no loss per share reported in Q2 2022[16] - For the six months ended June 30, 2023, the company reported a net loss of approximately $16.8 million, compared to a net loss of $7.98 million for the same period in 2022, representing a 110% increase in losses year-over-year[23] Cash and Assets - Cash and cash equivalents decreased to $13.33 million as of June 30, 2023, down from $34.67 million at the end of 2022, representing a 61.5% decline[15] - Total assets decreased to $23.21 million as of June 30, 2023, from $43.83 million at the end of 2022, indicating a 47% reduction[15] - The company's cash and cash equivalents decreased to approximately $13.3 million as of June 30, 2023, down from $32.1 million at the end of June 2022, indicating a decline of about 59%[23] - As of June 30, 2023, the Company reported cash equivalents of $10,837,944, a decrease from $33,238,658 as of December 31, 2022[41] Liabilities and Deficits - Current liabilities increased to $24.70 million as of June 30, 2023, compared to $31.62 million at the end of 2022, showing a 21.9% decrease[15] - The accumulated deficit grew to $157.88 million as of June 30, 2023, up from $141.07 million at the end of 2022, reflecting a worsening financial position[15] - The total accumulated deficit reached approximately $157.9 million as of June 30, 2023, compared to $118.1 million at the same time in 2022, reflecting an increase of approximately 34%[34] - The company has a working capital deficit of approximately $2.5 million as of June 30, 2023, indicating liquidity challenges[34] Research and Development - Research and development expenses for the first half of 2023 were $11.06 million, down from $12.60 million in the same period of 2022, a decrease of 12.2%[16] - The company plans to continue its focus on research and development activities to advance its product candidates through clinical development and regulatory approval[27] Capital and Funding - The company expects to require substantial additional capital to fund its operations and execute its current strategy over the next 12 months[35] - The company raised $1.3 million from the exercise of common stock warrants during the six months ended June 30, 2023, compared to $120,149 in the same period of 2022, showing a significant increase in capital raised[23] Licensing and Revenue - The Company has recognized $10.0 million in license fee revenue from its license agreement for XACIATO, all of which represents the upfront payment due[45] - The Company is entitled to receive up to $310.0 million in milestone payments related to the commercial sales of Ovaprene, contingent upon achieving specified milestones[50] - The license agreement with Organon includes tiered double-digit royalties based on net sales and up to $182.5 million in milestone payments[53] - The Company has not recognized any collaboration revenues as of June 30, 2023[44] - The Company has not recognized any royalty revenue as of June 30, 2023[46] Stock and Compensation - Total stock-based compensation expense for the six months ended June 30, 2023, was $1,274,807, compared to $1,069,930 for the same period in 2022, reflecting an increase of approximately 19.1%[100] - The number of shares of common stock available for future awards under the 2022 Stock Incentive Plan was 6,718,916 as of June 30, 2023[98] - The number of shares outstanding under the stock option plans increased from 6,612,554 at December 31, 2022, to 9,470,219 at June 30, 2023, reflecting an increase of approximately 43.5%[99] Agreements and Milestones - The Company agreed to pay former MBI stockholders up to $46.5 million contingent upon achieving specified funding, product development, and regulatory milestones[65] - The Company may pay MilanaPharm up to $500,000 upon the first commercial sale of licensed products in the U.S., and $1.0 million upon achieving $50 million in cumulative worldwide net sales[68] - The Company acquired Pear Tree Pharmaceuticals for exclusive rights to develop a proprietary formulation of tamoxifen, leading to the DARE-VVA1 program[70] - The Company agreed to pay former stockholders of Pear Tree up to $15.5 million for clinical milestones and up to $47 million for commercial milestones[72] Grants and Funding - The Company received a total of approximately $23.9 million in non-dilutive funding under the DARE-LARC1 grant agreement as of June 30, 2023, with a deferred grant funding liability of approximately $13.1 million recorded[123] - The Company received a grant of approximately $385,000 from NICHD on July 28, 2023, to support preclinical development for a new therapeutic[127]

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Commercial Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Catherine Novack – Jones Research Kumar Raja – ROTH Capital Kemp Dolliver – Brookline Capital Markets Doug Tsao – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company’s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incor ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright Kumaraguru Raja - ROTH Capital Joanne Lee - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exa ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Sabrina Johnson - President and Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Kumaraguru Raja - ROTH Capital Operator Welcome to the conference call hosted by Dare Bioscience to review the company's financial results for the quarter ended September 30, 2022 and to provide a general business update. This ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of I ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sabrina Johnson - President, CEO, Secretary & Director John A. Fair - Chief Strategy Officer Lisa Walters-Hoffert - CFO Conference Call Participants Operator Good . My name is Joanne, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dare Bioscience, Inc. Q2 2022 Conference Call. [Operator Instructions]. Ms. Johnson, you may begin your conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorp ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Zegbah Jallah - ROTH Capital Partners Douglas Tsao - H.C. Wainwright Kumaraguru Raja - Brookline Capital Markets Operator Welcome to the conference call hosted by Dare Bioscience to review the company's financial results f ...